Chicago, 29 May–2 June. More than 35,000 oncology professionals filled McCormick Place for the 2026 ASCO Annual Meeting under President Dr Eric Small’s chosen theme, “The Science and Practice of Translation: Improving Cancer Outcomes Worldwide.” The theme was fitting. This year’s ASCO was less about a single blockbuster readout and more about the industry finally landing several long-run scientific bets — pancreatic KRAS, ALK-positive lung, triple-negative breast, muscle-invasive bladder, and hepatocellular carcinoma — inside a single meeting. The programme carried more than 200 sessions across the four days; the plenary and late-breaker slots carried the year’s clearest signals.
Three storylines dominated the corridor conversations: the pancreatic-cancer plenary abstract from Revolution Medicines that changed a conversation the field had been pessimistic about for a decade; the long-term lorlatinib data that redefined the standard of care in ALK-positive non-small cell lung cancer; and the visibility of Chinese biotech readouts in solid-tumour indications where the industry had, historically, been Western-lead. Everything else — antibody-drug conjugates continuing their sweep, immunotherapy combinations getting better, AI creeping into trial operations — happened in the same context.
RASolute-302 and the pancreatic-cancer plenary
The single most-discussed abstract of the meeting was Revolution Medicines’ Phase 3 RASolute-302 trial of daraxonrasib, a next-generation KRAS inhibitor, in patients with KRAS-mutated metastatic pancreatic ductal adenocarcinoma. Selected as one of five plenary abstracts — the meeting’s most prestigious platform — the readout showed daraxonrasib nearly doubling overall survival compared with the current standard of care in a disease that has been resistant to therapeutic progress for a generation.
The clinical significance is difficult to overstate. Pancreatic cancer has, for most of the modern oncology era, been the field’s most stubborn indication. Median overall survival for metastatic PDAC has not moved by more than a handful of months across multiple therapeutic cycles. RASolute-302, if the data holds up in subgroup analyses and post-approval real-world evidence, is a step-change rather than an incremental gain. The follow-through — regulatory submission timing, combination-therapy development, biomarker refinement, and payer access — is where the next twenty-four months of the story lives.
Strategically, the abstract also validates the broader KRAS-programme thesis. Multiple companies have been pursuing next-generation KRAS inhibitors across mutation-specific and pan-KRAS designs. Daraxonrasib is the most convincing single readout the class has produced.
CROWN long-term: lorlatinib as the ALK-positive standard
The other plenary-tier result was the long-term follow-up of the Phase 3 CROWN trial in ALK-positive advanced non-small cell lung cancer. The numbers, at seven-year follow-up, were remarkable: patients on first-line lorlatinib reached a 7-year progression-free survival rate of 55%, compared with just 3% on crizotinib. In an era where NSCLC subtype-specific standards evolve on shorter time horizons than a decade, a seven-year PFS separation of that magnitude reframes the ALK-positive treatment paradigm.
The clinical implication is straightforward. Lorlatinib is now, on any reasonable read of the data, the de-facto first-line standard for ALK-positive advanced NSCLC. The subgroup and safety analyses continue to matter — neurocognitive effects, cardiovascular signals, and long-term tolerability are real considerations — but the survival benefit is the number the field will now anchor its treatment recommendations to.
Triple-negative breast: izalontamab brengitecan delivers
The breast-cancer track was, as usual, ADC-heavy. The result that captured the most attention was izalontamab brengitecan — a novel antibody-drug conjugate — in locally advanced or metastatic triple-negative breast cancer. The trial showed statistically significant and clinically meaningful improvements in both progression-free survival and overall survival compared with physician’s choice of chemotherapy. Triple-negative disease, which lacks the receptor-directed therapeutic options available to other breast-cancer subtypes, has been one of the ADC category’s clearest opportunities. Izalontamab brengitecan is the readout that turns that opportunity into a shipped product.
The strategic significance is that ADC data holds up across additional target-and-payload combinations, in additional tumour types, and against increasingly demanding comparators. The ADC category is not saturating; it is compounding.
Bladder: KEYNOTE-B15 / EV-304 confirms the perioperative move
The muscle-invasive bladder cancer readout — KEYNOTE-B15 / EV-304, evaluating perioperative enfortumab vedotin plus pembrolizumab versus neoadjuvant gemcitabine plus cisplatin — is the trial urologic oncology has been waiting for since the metastatic-setting readouts landed. The trial randomised 405 and 403 patients respectively and, at a median follow-up of 33.6 months, produced results that reshape the perioperative treatment paradigm for the disease.
The immediate clinical read is that the enfortumab-vedotin-plus-pembrolizumab combination is now the leading candidate for perioperative use in muscle-invasive disease. The commercial read is that the combination — already a well-established regimen in the metastatic setting — has a larger addressable population than the industry was previously pricing. Both are consequential.
The China chapter at ASCO
The most under-appreciated shift of the meeting was the increased visibility of Chinese biotechs on the ASCO platform. The clearest example was Oricell Therapeutics, which presented positive data from its Phase Ib BEACON study of Ori-C10, a GPC3-targeted CAR-T therapy, in late-line refractory hepatocellular carcinoma. The reported 50% objective response rate in efficacy-evaluable patients is a serious signal in a disease where late-line options are limited and CAR-T for solid tumours has, historically, disappointed.
Oricell is one example of a much larger trend. Chinese biotechs are showing up at ASCO with credible readouts, credible manufacturing processes, and — increasingly — the licensing partnerships that will bring the underlying assets to Western commercial markets. The industry’s licensing-in playbook, on full display at JPM in January, is playing out at ASCO in May.
AI in oncology, quietly useful
Beyond the therapeutic readouts, AI’s role in oncology continued its shift from headline to plumbing. Trial eligibility screening, imaging endpoint adjudication, patient-matching for cooperative-group trials, real-world-evidence pipelines, and adaptive-trial design were the workhorse applications. The results were less glamorous than the therapeutic readouts and, for the industry’s operational bottom line, arguably more consequential. Trials that enrol faster and finish cleaner produce readouts more predictably. That is the AI story oncology is actually shipping.
Immunotherapy combinations and the post-checkpoint conversation
The immuno-oncology track continued to move past first-generation checkpoint inhibitors into bispecifics, cell therapies in solid tumours, cancer vaccines paired with immunotherapy, and combination regimens designed for patients who do not respond to monotherapy. The science remains hard. The pipeline is increasingly modular. And the practical clinical outcome — which combinations move first-line care, which move salvage, and which get de-prioritised — is now the meeting’s most durable through-line.
What ASCO 2026 actually moved
- Pancreatic-cancer therapeutic pessimism has an answer. RASolute-302 changes the KRAS conversation.
- Lorlatinib is the ALK-positive NSCLC standard. Seven years of separation.
- ADCs keep compounding. Izalontamab brengitecan is the TNBC read.
- Enfortumab vedotin plus pembrolizumab moves perioperative. Muscle-invasive bladder gets a new standard.
- Chinese biotechs are on the ASCO platform. Ori-C10 will not be the last.
Open questions
Do the RASolute-302 survival numbers hold up in the post-approval real-world data, and does daraxonrasib expand into earlier-line and adjuvant use? Which of the ADCs in the current pipeline earn durable first-line positioning versus becoming crowded second-line options? And how quickly does the Chinese oncology pipeline translate from ASCO abstracts into Western regulatory approvals and payer contracts?
Bottom line: ASCO 2026 was the meeting where several long-run scientific bets finally landed at the same time. Pancreatic cancer has a therapeutic answer worth building around. ALK-positive lung has a durable first-line standard. Triple-negative breast has a new ADC option. Muscle-invasive bladder has a perioperative regimen. And the industry’s Chinese sourcing chapter has arrived on the plenary stage. Oncology, at ASCO 2026, felt like a field converting its long-run investments into shipped clinical practice. From here, the story is execution — payer access, real-world evidence, sequencing, and combinations.
